SILO PHARMA, INC. Proceeds from Sale and Maturity of Marketable Securities
SILO PHARMA, INC. (SILO) reported Proceeds from Sale and Maturity of Marketable Securities of $171.41 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2023-03-24
- SILO PHARMA, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2022-12-31 was $0.00, a 100.00% decline year-over-year.
- SILO PHARMA, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2022-09-30 was $0.00.
- SILO PHARMA, INC. proceeds from sale and maturity of marketable securities for the quarter ending 2021-12-31 was $279.09K.
- SILO PHARMA, INC. proceeds from sale and maturity of marketable securities for fiscal 2022 was $171.41K, a 52.37% decline from fiscal 2021.
- SILO PHARMA, INC. proceeds from sale and maturity of marketable securities for fiscal 2021 was $359.84K.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 3 month | Proceeds from Sale and Maturity of Marketable Securities 6 month | Proceeds from Sale and Maturity of Marketable Securities 9 month | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $0.00 derived: sum of 2 quarters · filed 2023-03-24 | $171.41K 10-K · filed 2023-03-24 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $171.41K 10-Q · filed 2022-11-10 | ||
| 2022-06-30 | $171.41K 10-Q · filed 2022-08-01 | |||
| 2021-12-31 | $279.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $359.84K 10-K · filed 2023-03-24 | ||
| 2021-09-30 | $80.75K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |